Frequency changes in HLA‐I alleles: A marker to guide immunotherapy in lung adenocarcinoma patients and its relationship with tumor mutational burden and PD‐L1 expression

Frequency changes in HLA‐I alleles: A marker to guide immunotherapy in lung adenocarcinoma patients and its relationship with tumor mutational burden and PD‐L1 expression

Abstract Background The aim of the study was to investigate differences in HLA‐I alleles between lung adenocarcinoma patients and healthy controls and determine their association with PD‐L1 expression and tumor mutational burden (TMB) to understand the mechanism underlying lung adenocarcinoma suscep...

Full description

Bibliographic Details
Main Authors: Xuanpeng Wu, Hao Wang, Fei Xue, Tao Jiang, Nanzheng Chen, Tianju Wang, Yong Zhang, Guangjian Zhang, Junke Fu, Qifei Wu
Format: Article
Language:English
Published: Wiley 2023-07-01
Series:Thoracic Cancer
Subjects:
allele
human leukocyte antigen
lung adenocarcinoma
PD‐L1
TMB
Online Access:https://doi.org/10.1111/1759-7714.14939
Description
Summary:Abstract Background The aim of the study was to investigate differences in HLA‐I alleles between lung adenocarcinoma patients and healthy controls and determine their association with PD‐L1 expression and tumor mutational burden (TMB) to understand the mechanism underlying lung adenocarcinoma susceptibility. Methods Differences in HLA allele frequencies between the two groups were analyzed in a case–control study. PD‐L1 expression and TMB in lung adenocarcinoma patients were determined and their relationships with HLA‐I were analyzed. Results The lung adenocarcinoma group showed significantly higher HLA‐A*30:01 (p = 0.0067, odds ratio [OR], 1.834; 95% confidence interval [CI]: 1.176–2.860), B*13:02 (p = 0.0050, OR, 1.855; 95% CI: 1.217–2.829), and C*06:02 (p = 0.0260, OR, 1.478; 95% CI: 1.060–2.060) and significantly lower B*51:01 (p = 0.0290, OR, 0.6019; 95% CI: 0.3827–0.9467), and C*14:02 (p = 0.0255, OR, 0.5089; 95% CI: 0.2781–0.9312) than the control group. Haplotype analysis results showed that HLA‐A*30:01–B*13:02 (p = 0.0100, OR, 1.909; 95% CI: 1.182–3.085), A*11:01–C*01:02 (p = 0.0056, OR, 1.909; 95% CI: 1.182–3.085), A*30:01–C*06:02 (p = 0.0111, OR, 1.846; 95% CI: 1.147–2.969), and B*13:02–C*06:02 (p = 0.0067, OR, 1.846; 95% CI: 1.147–2.969) frequencies significantly increased and B*51:01–C*14:02 (p = 0.0219, OR, 0.490; 95% CI: 0.263–0.914) frequency significantly decreased in lung adenocarcinoma patients. Three‐locus haplotype analysis showed that HLA‐A*30:01‐B*13:02‐C*06:02 frequency (p = 0.0100, OR, 1.909; 95% CI: 1.182–3.085) significantly increased in patients. Conclusion HLA‐A*30:01, B*13:02, and C*06:02 may be the susceptibility genes and HLA‐B*51:01 and C*14:01 act as the resistance genes of lung adenocarcinoma. The changes in HLA‐I allele frequencies had no association with PD‐L1 expression and TMB among these patients.
ISSN:1759-7706
1759-7714

Similar Items